PD-1 blockade induces responses by inhibiting adaptive immune resistance. Tumeh, et al., Science (2014) Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Spranger et Nature. (2015) Roche’s PD L1 inhibitor Tecentriq: a new contender in non small cell lung cancer, Clarivate...
所以,免疫检查点阻断(Immune Checkpoint Blockade)疗法是激活抗肿瘤免疫的有效方法。用抗体阻断免疫检查点,增强或抑制免疫细胞与“敌人”或“队友”间的交流信号,调节检查力度,即可增强原有的抗肿瘤免疫活性,为患者提供针对肿瘤的持久免疫应答。 在医学不断发展的今天,我们不仅知道免疫检查点在“检查什么”,还在一定程度...
而MSI阴性的病患,有效率很低,甚至是极低。 最新一份权威数据结果发布在国际顶级期刊《Science》上(Mismatch-repairdeficiencypredictsresponseofsolidtumorstoPD-1blockade)。在这项最新研究中,研究人员共招募了86名MSI阳性的、来自12种癌症的病患,并评估了PD-1抗体对这12种不同晚期肿瘤的治疗效果。 结果显示: 53%的...
是一种重要的免疫抑制分子。PD-1通过向下调节免疫系统对人体细胞的反应，以及通过抑制T细胞炎症活动来调节...
[7] Fournel L et al. Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer. Cancer Lett. 2019;464:5-14. [8] Herbst RS et al. Predictive correlates of response to the anti–PD-L1 antibody MPDL3280A in cancer patients. Nature. 201...
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer 抗PD-1 / PD-L1治疗的非小细胞肺癌患者出现疾病超进展 Annals of Oncology(影响因子:13.930) DOI:10.1093/annonc/mdz123 文献要点:1.PD-1...
[7]Zhang F, Wei H, Wang X, et al. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade[J]. Cell Discovery, 2017, 3:17004. [8]江苏康宁杰瑞皮下注射PD-L1抗体KN035的临床数据将在ASCO大会发布. [EB/OL]. [2020-08-11]. http://www.alphamabonc.com/html/news/2130...
3. Merryman,R.W., et al., Checkpoint blockade inHodgkin and non-Hodgkin lymphoma. Blood advances, 2017. 1(26): p. 2643-2654.
2. Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18): 1749-1755 3. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocar...
Pardoll. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer. 2012 Mar 22;12(4):252-64. [2].Annika De Sousa Linhares, Claire Battin, Sabrina Jutz, et al. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling[...